Every Form 4 that Inovio Pharmaceu (INO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INO filings page.
INOVIO PHARMACEUTICALS director Wendy L. Yarno received new equity awards as part of her non-employee director compensation. On May 20, 2026, she was granted 34,200 restricted stock units and options on 41,800 shares of common stock with a $1.23 exercise price.
The awards were granted under the 2023 Omnibus Incentive Plan. Both the restricted stock units and the stock options vest 100% on May 20, 2027, meaning they become fully earned on that date if service conditions are satisfied.
INOVIO PHARMACEUTICALS, INC. director Jay Shepard received equity awards as part of his non-employee director compensation. He was granted 34,200 restricted stock units, each representing a contingent right to one share of common stock, and 41,800 stock options with a $1.23 exercise price. Both the RSUs and the options were granted under the 2023 Omnibus Incentive Plan and are scheduled to vest 100% on May 20, 2027. These are compensation-related grants, not open-market purchases or sales.
INOVIO PHARMACEUTICALS, INC. director Ann Calby Miller received new equity awards as part of non-employee director compensation. She was granted 34,200 restricted stock units, each representing one future share of common stock, and 41,800 stock options with a $1.23 exercise price.
Both the RSUs and the options vest 100% on May 20, 2027 under the company’s 2023 Omnibus Incentive Plan. The options expire on May 20, 2036. These are compensation-related grants, not open‑market purchases or sales.
INOVIO PHARMACEUTICALS, INC. reported a routine equity compensation grant to director David B. Weiner. He was awarded 34,200 restricted stock units, each representing one share of common stock, and 41,800 common stock options with an exercise price of $1.23 per share. Both the RSUs and the options vest 100% on May 20, 2027, and the options expire on May 20, 2036. These awards were granted under the company’s 2023 Omnibus Incentive Plan pursuant to its non-employee director compensation policy and do not involve any open-market buying or selling of shares.
INOVIO PHARMACEUTICALS, INC. director Lota S. Zoth received new equity awards as part of non-employee director compensation. She was granted 34,200 restricted stock units, each representing one future share of common stock, and 41,800 stock options with a $1.23 exercise price.
Both the RSUs and options were granted under the company’s 2023 Omnibus Incentive Plan and are scheduled to vest 100% on May 20, 2027. These are compensation-related grants rather than open-market share purchases or sales.
INOVIO PHARMACEUTICALS, INC. director Roger D. Dansey received new equity compensation. On May 20, 2026, he was granted 34,200 restricted stock units and 41,800 stock options with a $1.23 exercise price. Both the RSUs and options vest 100% on May 20, 2027 under the 2023 Omnibus Incentive Plan.
INOVIO PHARMACEUTICALS director Simon X. Benito received new equity awards as part of his non-employee director compensation. On May 20, 2026, he was granted 34,200 restricted stock units, each representing one future share of common stock, and 41,800 stock options with a $1.23 exercise price.
Both the RSUs and options were granted under the 2023 Omnibus Incentive Plan and are scheduled to vest 100% on May 20, 2027, subject to applicable plan terms. These are compensation-related awards, not open-market share purchases or sales.
INOVIO PHARMACEUTICALS Chief Scientific Officer Laurent Humeau reported routine equity-compensation activity. On May 20, 2026, 6,027 restricted stock units vested, and 2,163 common shares were withheld at $1.23 per share to cover tax obligations, leaving him with 46,823 common shares held directly. He also received new awards of 27,440 restricted stock units and 34,160 stock options with a $1.73 exercise price, scheduled to vest in equal annual installments from February 26, 2027 through February 26, 2029.
INOVIO PHARMACEUTICALS, INC. Chief Medical Officer Michael John Sumner reported several equity compensation transactions on May 20, 2026. He exercised 9,450 restricted stock units, receiving common shares, and 2,693 shares were withheld by the company to cover related tax obligations.
Sumner also received a new grant of 37,684 restricted stock units, which vest in three annual installments from February 26, 2027 through February 26, 2029. In addition, he was granted 46,876 stock options with a $1.73 exercise price, vesting over the same three-year period under INOVIO’s amended 2023 Omnibus Incentive Plan, which shareholders approved on May 20, 2026.
INOVIO PHARMACEUTICALS, INC. CFO Peter Kies reported several equity compensation events on common stock and related awards. On May 20, 2026, 8,700 restricted stock units vested and were settled into common shares, with 4,688 shares withheld at a price of $1.23 to cover tax obligations. Following these transactions, he held 42,854 common shares directly and 375 common shares indirectly through his spouse. Kies also received new grants of 32,480 restricted stock units and 39,760 stock options with a $1.73 exercise price expiring on May 20, 2036, approved under Inovio’s amended and restated 2023 Omnibus Incentive Plan after shareholder approval.
INOVIO PHARMACEUTICALS, INC. reported routine equity compensation and related tax withholding transactions for CEO Jacqueline Elizabeth Shea. On May 20, 2026, 28,296 restricted stock units vested and were settled into common shares, with 12,306 shares withheld at $1.23 per share to cover tax obligations. Shea exercised a derivative award for 28,296 shares of common stock and, following this exercise, held 123,327 common shares directly, while after the tax withholding entry she held 111,021 shares directly. She also received new grants of 100,240 restricted stock units and 123,760 stock options with a $1.73 exercise price, vesting in equal annual installments from February 26, 2027 through February 26, 2029.
INOVIO PHARMACEUTICALS, INC. Chief Executive Officer Jacqueline Elizabeth Shea reported routine equity compensation activity involving restricted stock units. On May 15, 2026, 17,744 restricted stock units were exercised into common shares as part of a 53,233-unit award that vested in three annual tranches.
In connection with this vesting and settlement, the issuer withheld 7,717 shares of common stock at $1.30 per share to satisfy Shea’s tax withholding obligations, rather than selling shares in the open market. Following these transactions, Shea directly held 95,031 shares of INOVIO common stock.
INOVIO PHARMACEUTICALS, INC. CFO Peter Kies reported routine equity compensation activity involving restricted stock units. On May 15, 2026, 4,771 restricted stock units were exercised and converted into an equal number of common shares, consistent with a vesting schedule covering 14,313 units.
In a related transaction that day, 2,571 common shares were withheld by the issuer at $1.30 per share to satisfy Kies’s tax withholding obligations tied to this vesting and settlement. These tax-withholding shares were not an open-market sale.
Following these transactions, Kies directly holds 38,842 common shares, and his spouse indirectly holds an additional 375 common shares reported as indirect ownership.
INOVIO PHARMACEUTICALS, INC. Chief Scientific Officer Laurent Humeau reported routine equity compensation activity involving restricted stock units. On May 15, 2026, 4,771 restricted stock units converted into common stock, and 1,712 shares were withheld by the company to cover tax obligations. Following these transactions, Humeau directly holds 42,959 shares of common stock.
INOVIO PHARMACEUTICALS Chief Medical Officer Michael John Sumner exercised 2,385 restricted stock units into 2,385 shares of common stock on May 15, 2026. To cover related tax obligations, 680 shares were withheld by the company at $1.30 per share. After these transactions, he directly holds 35,281 shares of INOVIO common stock.
INOVIO PHARMACEUTICALS, INC. Chief Medical Officer Michael John Sumner exercised restricted stock units into common shares as part of a compensation award. A total of 4,292 restricted stock units vested and converted into 4,292 shares of common stock on March 31, 2026.
Of these shares, 1,223 were withheld by the company at a price of $1.74 per share to cover tax obligations tied to the vesting and settlement. After these routine compensation-related transactions, Sumner directly holds 33,576 shares of INOVIO common stock.
Humeau Laurent reported acquisition or exercise transactions in this Form 4 filing.
INOVIO PHARMACEUTICALS, INC. Chief Scientific Officer Laurent Humeau reported equity awards on common stock on March 4, 2026. He received a grant of 26,840 stock options vesting in three annual installments on February 26 of 2027, 2028 and 2029. He also received 21,560 restricted stock units, which vest in similar annual tranches from February 26, 2027 through February 26, 2029 and represent contingent rights to receive common shares, cash or a combination of both upon vesting.
INOVIO PHARMACEUTICALS, INC. Chief Executive Officer Jacqueline Elizabeth Shea reported equity awards consisting of stock options and restricted stock units. On March 4, 2026, she acquired 97,240 stock options and 78,760 restricted stock units as grants, each at a price of $0.00 per unit.
According to the vesting schedule, 32,414 of the options vest on February 26, 2027, 32,413 on February 26, 2028, and 32,413 on February 26, 2029. For the 78,760 restricted stock units, 26,254 vest on February 26, 2027, 26,253 on February 26, 2028, and 26,253 on February 26, 2029, with each unit representing a right to one share of common stock, settleable in stock, cash, or a combination.
Sumner Michael John reported acquisition or exercise transactions in this Form 4 filing.
INOVIO PHARMACEUTICALS, INC. reported that Chief Medical Officer Michael John Sumner received new equity awards. On March 4, 2026, he was granted options to purchase 36,832 shares of common stock and 29,608 restricted stock units.
The options vest in three annual installments: 12,278 shares on February 26, 2027, and 12,277 shares on each of February 26, 2028 and February 26, 2029. The restricted stock units vest similarly: 9,870 on February 26, 2027, then 9,869 on each of February 26, 2028 and February 26, 2029. Each restricted stock unit represents a right to receive one share of common stock, and vested units may be settled in stock, cash, or a combination.
INOVIO PHARMACEUTICALS, INC. CFO Peter Kies received equity awards in the form of stock options and restricted stock units on March 4, 2026. He was granted 31,240 common stock options at an exercise price of $0.0000 per share, all held as direct ownership.
The options vest in three installments: 10,414 shares on February 26, 2027, 10,413 shares on February 26, 2028, and 10,413 shares on February 26, 2029. He was also granted 25,520 restricted stock units, each representing a contingent right to receive one share of common stock, with 8,507 units vesting on February 26, 2027, 8,507 on February 26, 2028, and 8,506 on February 26, 2029. Vested restricted stock units can be settled in common stock, cash, or a combination of both.
INOVIO PHARMACEUTICALS, INC. Chief Scientific Officer Laurent Humeau reported several equity award-related transactions on February 26, 2026. He exercised restricted stock units into common stock in multiple tranches, including 5,010 and 7,366 units, each converting into an equal number of common shares at $0.00 per share.
In connection with these vesting and settlement events, the issuer withheld 2,064 and 3,034 common shares at a price of $1.79 per share to cover Mr. Humeau’s tax withholding obligations, as described in the footnotes. These are administrative equity award and tax-withholding transactions rather than open-market purchases or sales.
INOVIO PHARMACEUTICALS, INC. CFO Peter Kies reported equity award activity on February 26, 2026. He acquired 5,010 and 10,634 shares of common stock through the vesting and settlement of previously granted restricted stock units, at a stated price of $0.00 per share.
To cover related tax withholding obligations, the issuer withheld 2,965 and 6,294 shares at $1.79 per share, recorded as tax-withholding dispositions rather than open-market sales. Following these transactions, Kies held common stock directly and also had an indirect holding of 375 shares attributed to his spouse.
INOVIO PHARMACEUTICALS, INC. Chief Executive Officer Jacqueline Elizabeth Shea reported vesting of restricted stock units and related tax share withholdings. On February 26, 2026, 18,632 and 28,401 restricted stock units converted into the same number of common shares, while 8,057 and 13,657 shares were withheld to cover tax obligations.
INOVIO PHARMACEUTICALS, INC. Chief Medical Officer Michael John Sumner reported vesting and settlement of previously granted restricted stock units into common stock. On February 26, 2026 he acquired 5,010 and 11,550 shares of common stock upon exercise or conversion of vested restricted stock units granted in 2024 and 2025, respectively. A total of 3,903 common shares were withheld by the company at a price of $1.79 per share to cover his tax obligations related to this vesting. Following these transactions, Sumner directly owned 30,507 shares of INOVIO common stock.
INOVIO PHARMACEUTICALS director David B. Weiner acquired 972 shares of common stock through an RSU conversion. On February 26, 2026, 972 restricted stock units vested and were exercised at $0.00 per share, converting into 972 common shares.
These units were part of a 2,916‑unit grant made on February 27, 2023, vesting in three equal installments of 972 units on February 26 of 2024, 2025, and 2026. After this transaction, Weiner directly holds 87,592 shares of INOVIO common stock, and no restricted stock units from this grant remain outstanding.